BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

4D Molecular Therapeutics Inc. (NASDAQ:FDMT)

3 posts

Biotech News4D Molecular Therapeutics (FDMT) Price Target Signals 176% Upside

  • BioTech Health X
  • October 26, 2025
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is a clinical-stage biopharmaceutical company pioneering a new generation of genetic medicines through…
0 Shares
0
0
0
0
0
0
0

Biotech News4D Molecular Therapeutics Insider Sells $19,256 as FDMT Surges 27% in a Week

  • BioTech Health X
  • September 30, 2025
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is a clinical-stage biopharmaceutical company headquartered in Emeryville, California, dedicated to developing next-generation…
0 Shares
0
0
0
0
0
0
0

Biotech News4D Molecular (FDMT): The Gene Therapy Stock With 100%+ Upside Potential

  • BioTech Health X
  • August 1, 2025
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage biotechnology company dedicated to developing next-generation gene therapies using its…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Medtronic (MDT) Reports $9 Billion Revenue Surge
  • Boston Scientific (BSX) Set for a 25% Rally? Analysts Predict $127.55 Price Target
  • Kazia Therapeutics (KZIA) Faces NASDAQ Delisting After Missing Compliance Deadline — Is This the End?
  • Olema Pharma (OLMA) Surges After Roche’s Phase 3 Win Validates Oral SERDs
  • Is Fulcrum Therapeutics (FULC) the Next Rare-Disease Winner? New Data Says YES
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • November 19, 2025
    Medtronic (MDT) Reports $9 Billion Revenue Surge
    • November 19, 2025
    Boston Scientific (BSX) Set for a 25% Rally? Analysts Predict $127.55 Price Target
    • November 19, 2025
    Kazia Therapeutics (KZIA) Faces NASDAQ Delisting After Missing Compliance Deadline — Is This the End?
    • November 19, 2025
    Olema Pharma (OLMA) Surges After Roche’s Phase 3 Win Validates Oral SERDs
    • November 17, 2025
    Is Fulcrum Therapeutics (FULC) the Next Rare-Disease Winner? New Data Says YES
Recent Posts
  • Avalo Therapeutics (AVTX) Set for 167.86% Surge? Piper Sandler Reaffirms Massive $48 Price Target
    • November 17, 2025
  • Black Diamond Therapeutics (BDTX) Surges 115.9% YTD
    • November 17, 2025
  • Rhythm Pharma (RYTM) Surges as FDA Extends Review for IMCIVREE
    • November 17, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (559)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top